Dive into a collection of past posts and rediscover timeless content.
This quarter, a neuroscience company files its lead seizure drug with the FDA. Analyst targets run to $100. Here's the setup before the paperwork lands.
A medical imaging leader beat Q2 earnings by 9%, hit a record $23.9 billion backlog, and is reviewing its weakest segment for a potential sale.
This chocolate stock got punished when cocoa exploded, but the biggest pressure on margins is finally easing. The valuation now looks far more interesting.
The company that built the digital infrastructure of an entire economy trades at a massive discount to peers, reports Q2 Monday, and yields nearly 8%. Find out if the setup is worth the country risk.
An energy drink name just reported into sentiment that had already gone flat, with the Street looking for nearly 18% growth. The reaction is the real signal here.
The company that builds the boards inside AI switches and defense radar systems reports Q2 results tomorrow. Four consecutive earnings beats behind it and 55% growth expected. See if it belongs in your portfolio.
A rideshare name with improving ridership, quiet autonomous partnerships, and rock-bottom expectations reports Thursday. Clean cash flow quarter, and it reprices fast.
An aerospace alloys supplier has beaten estimates for four quarters in a row, has Q2 earnings next week with 40% expected growth. Find out if the setup is worth owning.
Everyone filed this away as a dying content delivery business. Security and cloud are now over half of revenue and growing double digits. Earnings August 6.